Sookoian S, Pirola CJ

Idioma: Ingles.
Referencias bibliográficas: 28
Paginas: 604-609
Archivo PDF: 1199.33 Kb.

FRAGMENTO

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher JJ, Bugianesi E et al. Nonalcoholic fatty liver disease. Nat Rev Dis Primers 2015; 1: 15080.

2. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015; 313: 2263-73.

3. Hannah WN, Jr., Harrison SA. Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2016; 61: 1365-74.

4. Rinella ME, Sanyal AJ. Management of NAFLD: a stage-based approach. Nat Rev Gastroenterol Hepatol 2016; 13: 196-205.

5. Brunt EM. Pathology of fatty liver disease. Mod Pathol 2007; 20 Suppl 1: S40-S48.

6. Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-Gomez M et al. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology 2016; 150: 1147-59.

7. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.

8. Brunt EM, Neuschwander-Tetri BA, Oliver D, Wehmeier KR, Bacon BR. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. Hum Pathol 2004; 35: 1070-82.

9. Sookoian S, Castano GO, Scian R, San MJ, Pirola CJ. Heat Shock Protein 27 is down-regulated in Ballooned Hepatocytes of Patients with Nonalcoholic Steatohepatitis (NASH). Sci Rep 2016; 6: 22528.

10. Francque S, Harrison SA, Sanyal A, Bedossa P, Serfaty L. Relationship between baseline hepatic disease severity and the cardiometabolic and anti-inflammatory effects of elafibranor in patients with non-alcoholic steatohepatitis. J Hepatology 2016; 64, S425-S630.

11. Cariou B, Hanf R, Lambert-Porcheron S, Zair Y, Sauvinet V, Noel B, Flet L et al. Dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care 2013; 36: 2923-30.

12. Herz M, Gaspari F, Perico N, Viberti G, Urbanowska T, Rabbia M, Wieczorek KD. Effects of high dose aleglitazar on renal function in patients with type 2 diabetes. Int J Cardiol 2011; 151: 136-42.

13. Wilding JP, Gause-Nilsson I, Persson A. Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes. Diab Vasc Dis Res 2007; 4: 194-203.

14. Suchanek KM, May FJ, Robinson JA, Lee WJ, Holman NA, Monteith GR, Roberts-Thomson SJ. Peroxisome proliferatoractivated receptor alpha in the human breast cancer cell lines MCF-7 and MDA-MB-231. Mol Carcinog 2002; 34: 165-71.

15. Michalik L, Desvergne B, Wahli W. Peroxisome-proliferatoractivated receptors and cancers: complex stories. Nat Rev Cancer 2004; 4: 61-70.

16. Hellemans K, Michalik L, Dittie A, Knorr A, Rombouts K, De JJ, Heirman C et al. Peroxisome proliferator-activated receptor- beta signaling contributes to enhanced proliferation of hepatic stellate cells. Gastroenterology 2003; 124: 184-201.

17. Hanf R, Millatt LJ, Cariou B, Noel B, Rigou G, Delataille P, Daix V et al. The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects. Diab Vasc Dis Res 2014; 11: 440-7.

18. Wang P, Liu J, Li Y, Wu S, Luo J, Yang H, Subbiah R et al. Peroxisome proliferator-activated receptor {delta} is an essential transcriptional regulator for mitochondrial protection and biogenesis in adult heart. Circ Res 2010; 106: 911-9.

19. Pirola CJ, Gianotti TF, Burgueno AL, Rey-Funes M, Loidl CF, Mallardi P, Martino JS et al. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. Gut 2013; 62: 1356-63.

20. Pirola CJ, Scian R, Gianotti TF, Dopazo H, Rohr C, Martino JS, Castano GO et al. Epigenetic Modifications in the Biology of Nonalcoholic Fatty Liver Disease: The Role of DNA Hydroxymethylation and TET Proteins. Medicine (Baltimore) 2015; 94: e1480.

21. Sookoian S, Pirola CJ. The genetic epidemiology of nonalcoholic fatty liver disease: toward a personalized medicine. Clin Liver Dis 2012; 16: 467-85.

22. Sookoian S, Pirola CJ. Epigenetics of insulin resistance: an emerging field in translational medicine. Curr Diab Rep 2013; 13: 229-37.

23. Cave MC, Clair HB, Hardesty JE, Falkner KC, Feng W, Clark BJ, Sidey J et al. Nuclear receptors and nonalcoholic fatty liver disease. Biochim Biophys Acta 2016.

24. Sookoian S, Rosselli MS, Gemma C, Burgueno AL, Fernandez GT, Castano GO, Pirola CJ. Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor gamma coactivator 1alpha promoter. Hepatology 2010; 52: 1992-2000.

25. Sookoian S, Pirola CJ. PNPLA3, the triacylglycerol synthesis/ hydrolysis/storage dilemma, and nonalcoholic fatty liver disease. World J Gastroenterol 2012; 18: 6018-26.

26. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53: 1883-94.

27. Ratziu V, Francque S, Harrison SA, Sanyal A, Bedossa P, Serfaty L, et al. PNPLA3 status in NASH is associated with oincreased histological severity at baseline but not with response to therapy in the GOLDEN-505 elafibranor trial. J Hepatology 2016; 64, S133-S158.

28. Hu Z, Ng DM, Yamada T, Chen C, Kawashima S, Mellor J, Linghu B et al. VisANT 3.0: new modules for pathway visualization, editing, prediction and construction. Nucleic Acids Res 2007; 35: W625-W632.